Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (766)	11/28/1997 12:20:00 PM
From: Alys Hall	Read Replies (1) \| Respond to of 3702

I've got a question about the odds that there will be year end selling which will further hinder any upside movement of the stock.Who has the answer to that scenario? Does it(price momentum)get affected more by an announcement of a credible CEO or by the downside pressure of year end selling? I heard some news on ABC about a treatment for NHL..was it Coulter or Idec? Where are we?..PATIENCE DOES WEAR THIN AFTER A WHILE!!!!

To: EZLibra who wrote (766)	12/1/1997 10:23:00 AM
From: EZLibra	Read Replies (1) \| Respond to of 3702

I hope everyone also enjoyed the holiday but it's over and I see there are several issues to address. I think I enjoyed the NY Times release on Rituxan the most; <The drug, Ritixan, was approved for treating so-called low-grade or follicular B-cell nonhodgkins lymphoma, a slow-growing but fatal and uncurable cancer of the immune system. It will be made and marketed by Genentech, Inc. of San Francisco.> It seems that Idec could not solve their manufacturing problems. <Rituxan is the first of a class of drugs called monoclonal antibodies to be approved for treating cancer, but FDA officials said there are at least two dozen such drugs in various stages of clinical trials..."Although it is not a cure, we finally have a cancer agent that can be effective with less serious side effects than with conventional chemotherapy," said Dr. Myron Czuczman, assistant professor of medicine at Roswell Park Cancer Institute in Buffalo, N.Y. and a key investigator of the new drug. "This is exciting news, especially for elderly patients and relapsed patients who have failed at least one standard treatment regimen."> What will the Idec bulls do when they wake up and discover Bexxar is a better drug for low grade NHL, or that Oncolym's market is twice that of Rituxan? Alys, some patience is required for the CEO search. What they have said is candidates will be presented to the board by year-end. These are not residents of the unemployment line but responsible and substantial members in good standing of Big Pharma/Biotech. I would think that the chosen one would have various affairs to wrap up before coming over. Meanwhile the science marches on. I hope everyone has been noticing all the publicity over EntreMed's angiostatin/endostatin antiangiogenesis. They are arresting cancer in mice by stopping new growth of blood vessels that feed solid tumors, thus leading to shrunken tumors. Many biotech/pharma's are doing this but ENMD is flying as if they were the only one. Other than patent turmoil the problem is that the tumors are extant and may regrow. Techniclone's antiangiogenesis kills the cancer and, for good measure, creates so much necrosis for TNT that any remaining malignant cells are mopped up. The patent estate is rock solid and, thus, Techniclone is the only game in town. This is a very big license. On the other hand TNT is generations ahead of the mouse stage and shouldn't even be compared to mammalian antiangiogenesis. I think the TNT trials of '98 will be looked upon as a milestone event for all cancer therapeutics. What is a cure for cancer worth? To Alys again, any tax-selling now is usually amateur and should be taken advantage of. This stock at this price is a steal.